<< Pharma manufacturer's failure to disclose endangers Swine Flu vaccination program | FDA approves DuraSeal spine sealant for the U.S. market >>
Read in | English | 日本語

Report on multinational and domestic strategies in emerging markets

Published on September 8, 2009 at 7:29 AM · No Comments

Reportlinker.com announces that a new market research report is available in its catalogue.

The emerging markets are luring a growing number ofst pharma companies looking to compensate for the diminishing revenues in developed markets. Latin America and Central and Eastern Europe (CEE) are showing strong growth rates, proving to be lucrative targets for firms aiming to expand their foothold, initially as a generics player, but also providing a foundation for subsequent brand penetration.

Scope

  • Provides an overview of recent events affecting the generics market in the CEE and Latin America
  • Identifies the different barriers and opportunities for growth in the CEE and Latin America
  • Provides insight into the growth drivers of multinational and domestic generic players operating in these regions
  • Identifies key strategies for entrance and expansion in these markets

Highlights

Sales growth in the CEE generics market is slowing due to increasing competition among generics players, while the Latin American market continues to grow, with significant room for further expansion. Consequently, the Latin American market offers multinationals a better opportunity due to is comparatively greater growth potential.

Indian generics firms are showing a growing interest in the Latin American generics market, especially Brazil. However, going forward, this may undermine the success of domestic players in this region, as Indian generics companies have a ready source of active pharmaceutical ingredients (APIs) and an established low cost manufacturing base.

Generic penetration across the CEE is consistently high due to the historically poor enforcement of intellectual property (IP) laws. However IP issues and competition from similares (non-bioequivalent drugs) hamper penetration of true generics in Latin America, although new regulations have been implemented to target this issue.

Reasons to Purchase

  • Understand how recent events and trends will affect the generics industry in the CEE and Latin America
  • Gain insight into which companies are growing rapidly and which strategies are employed
  • Identify the different benefits of entering the CEE and Latin American markets

http://www.reportlinker.com/

Posted in: Pharmaceutical News

Tags:

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading